Ceftazidime and Avibactam
Brand names: Avycaz · Active ingredient: Ceftazidime, Avibactam Sodium
In short: AVYCAZ (ceftazidime and avibactam) in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli
What is Ceftazidime and Avibactam used for?
AVYCAZ (ceftazidime and avibactam) in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli
,
Klebsiella
pneumoniae
,
Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca,
Citrobacter
freundii complex, and Pseudomonas aeruginosa
.
AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Escherichia coli
,
Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter
freundii complex, Proteus
mirabilis
, and Pseudomonas aeruginosa
.
AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae. …
Ceftazidime and Avibactam dosage
The recommended dosage of AVYCAZ is 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) administered every 8 hours by intravenous (IV) infusion over 2 hours in patients 18 years of age and older with CrCl greater than 50 mL/min. For treatment of cIAI, metronidazole should be given concurrently. The guidelines for dosage of AVYCAZ in patients with creatinine clearance (CrCl) greater than 50 mL/min are listed in Table 1
.
Table 1.
Dosage of AVYCAZ 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) by Indication
in Adult Patients (18 years of age and older)
Infection | Dos
e | Frequency | Infusion Time
(hours) | Duration of Treatment
Complicated Intra-abdominalInfections (cIAI)* | 2.5 grams | Every 8 hours | 2 | cIAI: 5 to 14 dayscUTI: 7 to 14 daysHABP/VABP: 7 to 14 days
Complicated Urinary TractInfections including Pyelonephritis (cUTI)
Hospital-acquired BacterialPneumonia and Ventilator-associatedBacterial Pneumonia (HABP/VABP)
* Used in conjunction with metronidazole 0.5 g intravenously every 8 hours in adult cIAI patients .
The recommended dosage of AVYCAZ in pediatric patients aged 2 years to less than 18 years and an estimated glomerular filtration rate (eGFR) greater than 50 mL/min/1.73 m2 and in pediatric patients less than 2 years of age without renal impairment is described in Table 2. AVYCAZ is administered every 8 hours by intravenous infusion over 2 hours. For treatment of cIAI, metronidazole should be given concurrently.
Table 2.
Dosage of AVYCAZ (ceftazidime and avibactam) in
Pediatric
Patients
Infection | Age Range | Dose | Frequency | Infusion Time (hours) | Duration of treatment
cIAI*, cUTI including Pyelonephritis, and HABP/VABP | 2 years to less than 18 yearsa | AVYCAZ 62.5 mg/kg to a maximum of 2.5 grams (ceftazidime 50 mg/kg and avibactam 12.5 mg/kg to a maximum dose of ceftazidime 2 grams and avibactam 0.5 grams) | Every 8 hours | 2 | cIAI: 5 to 14 dayscUTI: 7 to 14 days HABP/VABP: 7 to 14 days
6 months to less than 2 years | AVYCAZ 62.5 mg/kg (ceftazidime 50 mg/kg and avibactam 12.5 mg/kg)
3 months to less than 6 months | AVYCAZ 50 mg/kg (ceftazidime 40 mg/kg and avibactam 10 mg/kg)
Greater than 28 daysb to less than 3 months | AVYCAZ 37.5 mg/kg (ceftazidime 30 mg/kg and avibactam 7.5 mg/kg)
Less than or equal to 28 daysc with GA 31 weeks and older | AVYCAZ 25 mg/kg (ceftazidime 20 mg/kg and avibactam 5 mg/kg)
*AVYCAZ was used in conjunction with metronidazole 10 mg/kg intravenously every 8 hours in pediatric cIAI patients
a
For pediatric patients (aged 2 years and older) with eGFR less than or equal to 50 mL/min/1.73m2, dosage adjustments are recommended [
s
ee Dosage and Administration (
2.3
)].
b Includes full-term infants with PNA > 28 days and pre-term infants with corrected age > 28 days. …
How to take Ceftazidime and Avibactam — instructions & advice from the label
Serious Allergic Reactions
Advise patients, their families, or caregivers that allergic reactions, including serious allergic reactions, could occur that require immediate treatment. Ask them about any previous hypersensitivity reactions to AVYCAZ, other beta-lactams (including cephalosporins), or other allergens .
Potentially Serious Diarrhea
Advise patients, their families, or caregivers that diarrhea is a common problem caused by antibacterial drugs. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, tell them to contact his or her healthcare provider .
Nervous System Reactions
Advise patients, their families, or caregivers that neurological adverse reactions can occur with AVYCAZ use. Instruct patients their families, or caregivers to inform a healthcare provider at once of any neurological signs and symptoms, including encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), myoclonus, and seizures, for immediate treatment, dosage adjustment, or discontinuation of AVYCAZ . …
Warnings & precautions
Do not take this medicine if: AVYCAZ is contraindicated in patients with known serious hypersensitivity to the components of AVYCAZ (ceftazidime and avibactam), avibactam containing products, or other members of the cephalosporin class
.
In a Phase 3 cIAI trial in adult patients, clinical cure rates were lower in a subgroup of patients with baseline CrCl of 30 to less than or equal to 50 mL/min compared to those with CrCl greater than 50 mL/min (Table 10). The reduction in clinical cure rates was more marked in patients treated with AVYCAZ plus metronidazole compared to meropenem-treated patients. Within this subgroup, patients treated with AVYCAZ received a 33% lower daily dose than is currently recommended for patients with CrCl 30 to less than or equal to 50 mL/min.
The decreased clinical response was not observed for patients with moderate renal impairment at baseline (CrCl of 30 to less than or equal to 50 mL/min) in the Phase 3 cUTI trials or the Phase 3 HABP/VABP trial.
Monitor CrCl at least daily in adult and pediatric patients with changing renal function and adjust the dosage of AVYCAZ accordingly [
see
Dosage and Administration
(
2.2
,
2.3
)
,
and
Adverse Reactions (
6.1
)
]
.
Table 10.
Clinical Cure Rate at Test of Cure in a Phase 3
cIAI
Trial, by Baseline Renal Function – mMITT
Population
a
AVYCAZ
+ Metronidazole
% (n/N) | Meropenem
% (n/N)
Normal function / mild impairment(CrCl greater than 50 mL/min) | 85% (322/379) | 86% (321/373)
Moderate impairment(CrCl 30 to less than or equal to 50 mL/min) | 45% (14/31) | 74% (26/35)
a
Microbiological modified intent-to-treat (mMITT) population included patients who had at least one bacterial pathogen at baseline and received at least one dose of study drug. …
Ceftazidime and Avibactam side effects
The following adverse reactions are discussed in greater detail in the Warnings and Precautions section:
Hypersensitivity Reactions
Clostridi
oid
e
s
difficile-Associated Diarrhea
Central Nervous System Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience in Adult Patients
AVYCAZ was evaluated in six active-controlled clinical trials in patients with cIAI, cUTI, including pyelonephritis, or HABP/VABP. These trials included two Phase 2 trials, one in cIAI and one in cUTI, as well as four Phase 3 trials, one in cIAI, one in cUTI (Trial 1), one in cIAI or cUTI due to ceftazidime non-susceptible pathogens (Trial 2), and one in HABP/VABP. Data from cUTI Trial 1 served as the primary dataset for AVYCAZ safety findings in cUTI as there was a single comparator. cUTI Trial 2 had an open-label design as well as multiple comparator regimens which prevented pooling but provided supportive information. The six clinical trials included a total of 1809 adult patients treated with AVYCAZ and 1809 patients treated with comparators. …
Drug interactions
In vitro, avibactam is a substrate of OAT1 and OAT3 transporters which might contribute to the active uptake from the blood compartment, and thereby its excretion. As a potent OAT inhibitor, probenecid inhibits OAT uptake of avibactam by 56% to 70% in vitro and, therefore, has the potential to decrease the elimination of avibactam when co-administered. Because a clinical interaction study of AVYCAZ or avibactam alone with probenecid has not been conducted, co-administration of AVYCAZ with probenecid is not recommended
.
The administration of ceftazidime may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
About this medicine
AVYCAZ is an antibacterial combination product consisting of the semisynthetic cephalosporin ceftazidime pentahydrate and the beta-lactamase inhibitor avibactam sodium for intravenous administration.
Ceftazidime
Ceftazidime is a semisynthetic, beta-lactam antibacterial drug. It is the pentahydrate of (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate. Its molecular weight is 636.6. The empirical formula is C22H32N6O12S2.
Figure 1.
Chemical structure of ceftazidime pentahydrate
Avibactam
Avibactam sodium chemical name is sodium [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] sulfate. Its molecular weight is 287.23. The empirical formula is C7H10N3O6SNa.
Figure
2.
Chemical structure of avibactam sodium
AVYCAZ 2.5 grams (ceftazidime and avibactam) for injection is a white to yellow sterile powder for constitution consisting of ceftazidime pentahydrate and avibactam sodium packaged in glass vials. The formulation also contains sodium carbonate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin